{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:31:15Z","timestamp":1787761875738,"version":"build-2784847793"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"unspecified","delay-in-days":136,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32441090"],"award-info":[{"award-number":["32441090"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003711","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["2021YFC2501300"],"award-info":[{"award-number":["2021YFC2501300"]}],"id":[{"id":"10.13039\/501100003711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["23"],"award-info":[{"award-number":["23"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["25-27"],"award-info":[{"award-number":["25-27"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","award":["Z201100005520022"],"award-info":[{"award-number":["Z201100005520022"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chinese National Key Technology R&D Program"},{"name":"Chinese National Key Technology R&D Program, Ministry of Science and Technology","award":["2024YFC2510300"],"award-info":[{"award-number":["2024YFC2510300"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-013"],"award-info":[{"award-number":["2022-PUMCH-B-013"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-D-001"],"award-info":[{"award-number":["2025-PUMCH-D-001"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["C-002"],"award-info":[{"award-number":["C-002"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["D-009"],"award-info":[{"award-number":["D-009"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-005"],"award-info":[{"award-number":["2021-I2M-1-005"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-1-004"],"award-info":[{"award-number":["2022-I2M-1-004"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-2-005"],"award-info":[{"award-number":["2023-I2M-2-005"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2025,11,1]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-centre, prospective cohort study (January 2012 to April 2024) consecutively enrolled patients with aPLs-TP from Peking Union Medical College Hospital. Inclusion required persistent aPL positivity (\u226512 weeks apart) and platelet (PLT) count &lt;100\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L twice, excluding secondary causes. Demographic aPL profiles and clinical outcomes (thrombosis, pregnancy morbidity, microangiopathy and valve disease) were analysed. Hierarchical clustering and Kaplan-Meier survival analysis were performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 123 patients (65.9% female, mean age 36.0 years) were consecutively enrolled in the study. Median PLT count was 50.0\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Three clusters were identified: cluster 1 (n=35, all male, median PLT 67.0\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) consisted of men with smoking history, hyperhomocysteinaemia and diabetes, demonstrating the highest rate of atherothrombotic and valvular events; cluster 2 (n=51, all female, median PLT 60.0\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) included females with recurrent pregnancy morbidity and mild anaemia; and cluster 3 (n=37, 81.1% female, median PLT 27.0\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) comprised patients with isolated severe thrombocytopenia with the lowest rate of complete remission. Analysis of event-free survival for key clinical outcomes differed significantly among clusters at 5 years (p=0.026): cluster 1 at 66.9% (95% CI 52.50 to 85.24), cluster 2 at 45.85% (95% CI 32.41 to 64.86) and cluster 3 at 88.68% (95% CI 78.80 to 99.80).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Significant heterogeneity exists in patients with aPLs-TP, thus making PLT count alone an inadequate predictor of clinical phenotypes and prognosis. Subgroup analysis leveraging distinct clinical features is essential to develop individualised treatment strategies and improve outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001761","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T08:05:23Z","timestamp":1763107523000},"page":"e001761","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Phenotypically driven subgroups of primary antiphospholipid syndrome-associated thrombocytopenia display distinct outcomes: a prospective cohort study with cluster analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5651-7404","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"first","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0148-301X","authenticated-orcid":false,"given":"Ruijie","family":"Mo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"},{"name":"4+4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4565-7607","authenticated-orcid":false,"given":"Can","family":"Huang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangzhong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8447-8121","authenticated-orcid":false,"given":"Liying","family":"Peng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-7984","authenticated-orcid":false,"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shi","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Ding","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2331-251X","authenticated-orcid":false,"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-9738","authenticated-orcid":false,"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9308-2858","authenticated-orcid":false,"given":"Jiuliang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2025111400050987000_12.2.e001761.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705454"},{"key":"2025111400050987000_12.2.e001761.2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"Knight","year":"2023","journal-title":"BMJ"},{"key":"2025111400050987000_12.2.e001761.3","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.2015.0197"},{"key":"2025111400050987000_12.2.e001761.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.10187"},{"key":"2025111400050987000_12.2.e001761.5","first-page":"174","article-title":"Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus (Los Angel)"},{"key":"2025111400050987000_12.2.e001761.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.002"},{"key":"2025111400050987000_12.2.e001761.7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac264"},{"key":"2025111400050987000_12.2.e001761.8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.46497\/ArchRheumatol.2022.9088","article-title":"Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index","volume":"37","author":"Gamal","year":"2022","journal-title":"Arch Rheumatol"},{"key":"2025111400050987000_12.2.e001761.9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejim.2020.10.011","article-title":"Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia","volume":"84","author":"Moulinet","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2025111400050987000_12.2.e001761.10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000595","article-title":"Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome","volume":"31","author":"Vreede","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2025111400050987000_12.2.e001761.11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s40744-023-00538-0","article-title":"Immune Thrombocytopenia Could be an Independent Clinical Phenotype of Antiphospholipid Syndrome: A Prospective Cohort Study","volume":"10","author":"Shi","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025111400050987000_12.2.e001761.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"2025111400050987000_12.2.e001761.13","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR Antiphospholipid Syndrome Classification Criteria","volume":"75","author":"Barbhaiya","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025111400050987000_12.2.e001761.14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.medj.2024.06.005","article-title":"Phenotypic subgroup in serologically active clinically quiescent systemic lupus erythematosus: A cluster analysis based on CSTAR cohort","volume":"5","author":"Ding","year":"2024","journal-title":"Med"},{"key":"2025111400050987000_12.2.e001761.15","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1007\/s10238-023-01195-x","article-title":"Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study","volume":"23","author":"Long","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025111400050987000_12.2.e001761.16","doi-asserted-by":"publisher","DOI":"10.2478\/rir-2022-0033"},{"key":"2025111400050987000_12.2.e001761.17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"key":"2025111400050987000_12.2.e001761.18","doi-asserted-by":"crossref","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025111400050987000_12.2.e001761.19","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/rheumatology\/kead498","article-title":"Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study","volume":"63","author":"Jiang","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025111400050987000_12.2.e001761.20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.medcli.2016.11.026","article-title":"Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria","volume":"148","author":"Demetrio Pablo","year":"2017","journal-title":"Med Clin (Barc)"},{"key":"2025111400050987000_12.2.e001761.21","first-page":"531","article-title":"Value of an extensive biological study in venous or arterial thromboses","volume":"25","author":"Tazi","year":"1996","journal-title":"Presse Med"},{"key":"2025111400050987000_12.2.e001761.22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-0037-1614438","article-title":"Hyperhomocysteinemia, atherosclerosis and thrombosis","volume":"81","author":"Cattaneo","year":"1999","journal-title":"Thromb Haemost"},{"key":"2025111400050987000_12.2.e001761.23","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/rheumatology\/keab475","article-title":"Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study","volume":"61","author":"Pardos-Gea","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025111400050987000_12.2.e001761.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00834-4"},{"key":"2025111400050987000_12.2.e001761.25","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3390\/ijms22084200","article-title":"VWF, Platelets and the Antiphospholipid Syndrome","volume":"22","author":"Huang","year":"2021","journal-title":"IJMS"},{"key":"2025111400050987000_12.2.e001761.26","doi-asserted-by":"crossref","first-page":"109790","DOI":"10.1016\/j.clim.2023.109790","article-title":"Risk factors in antiphospholipid antibody-associated valvular heart disease: A 383-patient cohort study","volume":"256","author":"Pan","year":"2023","journal-title":"Clin Immunol"},{"key":"2025111400050987000_12.2.e001761.27","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082996","article-title":"Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre","volume":"12","author":"Pons","year":"2023","journal-title":"J Clin Med"},{"key":"2025111400050987000_12.2.e001761.28","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jacc.2024.12.032","article-title":"Association Between Cigarette Smoking and Subclinical Markers of Cardiovascular Harm","volume":"85","author":"Yao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2025111400050987000_12.2.e001761.29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00864","article-title":"Risk Factors for Adverse Maternal and Fetal Outcomes in Women With Confirmed aPL Positivity: Results From a Multicenter Study of 283 Pregnancies","volume":"9","author":"Fredi","year":"2018","journal-title":"Front Immunol"},{"key":"2025111400050987000_12.2.e001761.30","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060671","article-title":"Low Preconception Complement Levels Are Associated with Adverse Pregnancy Outcomes in a Multicenter Study of 260 Pregnancies in 197 Women with Antiphospholipid Syndrome or Carriers of Antiphospholipid Antibodies","volume":"9","author":"Nalli","year":"2021","journal-title":"Biomedicines"},{"key":"2025111400050987000_12.2.e001761.31","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030675","article-title":"Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review","volume":"11","author":"Alijotas-Reig","year":"2022","journal-title":"J Clin Med"},{"key":"2025111400050987000_12.2.e001761.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.placenta.2008.07.008"},{"key":"2025111400050987000_12.2.e001761.33","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/25785826.2023.2213976","article-title":"Involvement of the complement system in immune thrombocytopenia: review of the literature","volume":"46","author":"Shindo","year":"2023","journal-title":"Immunol Med"},{"key":"2025111400050987000_12.2.e001761.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971005","article-title":"Thrombocytopenia in the first trimester predicts adverse pregnancy outcomes in obstetric antiphospholipid syndrome","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"2025111400050987000_12.2.e001761.35","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213"},{"key":"2025111400050987000_12.2.e001761.36","doi-asserted-by":"crossref","first-page":"100638","DOI":"10.1016\/j.blre.2019.100638","article-title":"Thrombocytopenia in pregnancy: Diagnosis and approach to management","volume":"40","author":"Pishko","year":"2020","journal-title":"Blood Rev"},{"key":"2025111400050987000_12.2.e001761.37","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejim.2020.01.017","article-title":"Thrombocytopenia in primary antiphospholipid syndrome, a marker of high-risk patients?","volume":"74","author":"Yelnik","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2025111400050987000_12.2.e001761.38","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/10245332.2018.1532649","article-title":"Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study","volume":"24","author":"Frison","year":"2019","journal-title":"Hematology"},{"key":"2025111400050987000_12.2.e001761.39","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0038-1649646","article-title":"Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation","volume":"70","author":"Martinuzzo","year":"1993","journal-title":"Thromb Haemost"},{"key":"2025111400050987000_12.2.e001761.40","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9091170","article-title":"Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?","volume":"9","author":"Tomasello","year":"2021","journal-title":"Biomedicines"},{"key":"2025111400050987000_12.2.e001761.41","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13030741","article-title":"Platelets and Thrombotic Antiphospholipid Syndrome","volume":"13","author":"Tohidi-Esfahani","year":"2024","journal-title":"J Clin Med"},{"key":"2025111400050987000_12.2.e001761.42","article-title":"Role of Direct Oral Anticoagulation Agents as Thromboprophylaxis in Antiphospholipid Syndrome","volume":"13","author":"Arora","year":"2021","journal-title":"Cureus"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001761","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T08:05:27Z","timestamp":1763107527000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,13]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/lupus-2025-001761"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001761","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}